These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23824994)

  • 41. Meta-analyses triggered by previous (false-)significant findings: problems and solutions.
    Schuit E; Roes KC; Mol BW; Kwee A; Moons KG; Groenwold RH
    Syst Rev; 2015 Apr; 4():57. PubMed ID: 25908184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inconsistent treatment estimates from mis-specified logistic regression analyses of randomized trials.
    Matthews JN; Badi NH
    Stat Med; 2015 Aug; 34(19):2681-94. PubMed ID: 25869059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting clinical trial results based on announcements of interim analyses.
    Broglio KR; Stivers DN; Berry DA
    Trials; 2014 Mar; 15():73. PubMed ID: 24607270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stopping trials for efficacy: an almost unbiased view.
    Goodman SN
    Clin Trials; 2009 Apr; 6(2):133-5. PubMed ID: 19342465
    [No Abstract]   [Full Text] [Related]  

  • 45. Consequences of sequential sampling for meta-analysis.
    Braschi L; Botella J; Suero M
    Behav Res Methods; 2014 Dec; 46(4):1167-83. PubMed ID: 24399083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A decision-theoretic evaluation of early stopping rules.
    Heitjan DF; Houts PS; Harvey HA
    Stat Med; 1992 Mar; 11(5):673-83. PubMed ID: 1594809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimation of the treatment effect following a clinical trial that stopped early for benefit.
    Marschner IC; Schou M; Martin AJ
    Stat Methods Med Res; 2022 Dec; 31(12):2456-2469. PubMed ID: 36065593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit.
    Murad MH; Guyatt GH; Domecq JP; Vernooij RWM; Erwin PJ; Meerpohl JJ; Prutsky GJ; Akl EA; Mueller K; Bassler D; Schandelmaier S; Walter SD; Busse JW; Kasenda B; Pagano G; Pardo-Hernandez H; Montori VM; Wang Z; Briel M
    J Clin Epidemiol; 2017 Feb; 82():12-19. PubMed ID: 27832953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Roaming through the methodology. XIV. The premature ending of a randomized trial].
    Vandenbroucke JP
    Ned Tijdschr Geneeskd; 1999 Jun; 143(25):1305-8. PubMed ID: 10416484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events.
    Hazelbag CM; Klungel OH; van Staa TP; de Boer A; Groenwold RH
    Ann Epidemiol; 2015 Aug; 25(8):590-6. PubMed ID: 25935711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early stopping of randomized clinical trials for overt efficacy is problematic.
    Bassler D; Montori VM; Briel M; Glasziou P; Guyatt G
    J Clin Epidemiol; 2008 Mar; 61(3):241-6. PubMed ID: 18226746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Practical problems in interim analyses, with particular regard to estimation.
    Pocock SJ; Hughes MD
    Control Clin Trials; 1989 Dec; 10(4 Suppl):209S-221S. PubMed ID: 2605969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A meta-analysis of criterion effects for the Implicit Relational Assessment Procedure (IRAP) in the clinical domain.
    Vahey NA; Nicholson E; Barnes-Holmes D
    J Behav Ther Exp Psychiatry; 2015 Sep; 48():59-65. PubMed ID: 25727521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correcting overestimated effect size estimates in multiple trials.
    Wiedermann W; Gula B; Czech P; Muschik D
    J Gen Psychol; 2011; 138(4):292-9. PubMed ID: 24836567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Commentary: Empirical evidence of attrition bias in clinical trials.
    Jüni P; Egger M
    Int J Epidemiol; 2005 Feb; 34(1):87-8. PubMed ID: 15649954
    [No Abstract]   [Full Text] [Related]  

  • 56. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.
    Korn EL; Freidlin B; Mooney M
    J Clin Oncol; 2009 Apr; 27(10):1712-21. PubMed ID: 19237631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early stopping in clinical trials and epidemiologic studies for "futility": conditional power versus sequential analysis.
    van der Tweel I; van Noord PA
    J Clin Epidemiol; 2003 Jul; 56(7):610-7. PubMed ID: 12921928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Point estimation for adaptive trial designs II: Practical considerations and guidance.
    Robertson DS; Choodari-Oskooei B; Dimairo M; Flight L; Pallmann P; Jaki T
    Stat Med; 2023 Jun; 42(14):2496-2520. PubMed ID: 37021359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials.
    Toyoizumi K; Matsui S
    Stat Med; 2022 Nov; 41(26):5276-5289. PubMed ID: 36055340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Avoiding bias and incorrect confidence interval coverage in prescription drug labeling.
    Levin G
    Clin Trials; 2016 Apr; 13(2):199-204. PubMed ID: 26572563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.